Co-founder and Managing Partner at Peppermint VenturePartners 

Klaus Stoeckemann is a co-founder and Managing Partner of Peppermint VenturePartners (PVP) (www.peppermint-vp.com) managing the Peppermint Charité Biomedical Fund (CBF I) and the Helmholtz Validation Fund. He has more than 28 years of experience in the international healthcare industry. Starting in the pharmaceutical industry in 1992 he worked in different leading positions at Schering AG (now Bayer) and Asta Medica (Degussa). He moved into Venture Capital end of 1999 joining 3i where he became General Partner in the Healthcare team. He is responsible for more than 15 investments and exits including the IPO’s of Epigenomics, Jerini and others as well as trade-sales of Amaxa and Elbion.

He currently is chairman of the boards of the digital health companies Emperra and Caterna and Vice Chairman of Implandata and board member of Humedics, all portfolio companies of the CBF I. As mentor for different accelerators as well as member of the board of the German Association of Venture Capital (BVK) he assists to build the Start-Up and Venture Capital ecosystem in Germany. Klaus holds a PhD in Biology and Pharmacology from the University of Mainz as well as a MBA from WHU / Kellogg Northwestern University in the US.